Loading
Anirban Maitra is a pancreatic cancer pathologist working on catching the disease early and understanding its precursors.
Anirban Maitra is Scientific Director of the Sheikh Ahmed Center for Pancreatic Cancer Research at MD Anderson Cancer Center. A pathologist and pancreatic cancer researcher, he leads early-detection efforts including the pancreatic cancer risk and cyst programmes, and studies the biology of pancreatic precursor lesions and KRAS-driven tumorigenesis. His papers include a Gastroenterology review of the opportunities and challenges in early detection of pancreatic cancer and a Modern Pathology analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. His work connects pancreatic ductal adenocarcinoma pathology to multi-cancer early detection and liquid biopsy.
| Title | Journal | Year |
|---|---|---|
| Early Detection of Pancreatic Cancer: Opportunities and Challenges | Gastroenterology | 2019 |
| Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray | Modern Pathology | 2003 |
Fixes the window in which a blood test could plausibly work and shows why CA 19-9 alone is not enough: half of early cases are missed even at diagnosis, and Lewis-negative patients are missed entirely.
Exosome DNA adds signal where free DNA is scarce, particularly after neoadjuvant treatment, and the two together give the strongest published blood-based prognosis in this disease.
It fixed the working numbers for a comprehensive panel in pancreatic cancer: a hit worth acting on in about one patient in six, most of it in repair genes and the KRAS wild-type minority.
It fixes the order of events, with the initiating mutation present in the smallest visible lesion, and it warns that finding mutant KRAS in a duct does not mean cancer.
A GNAS mutation in cyst fluid says the cyst is an IPMN, and in a cancer it says the cancer came from one, which is the molecular basis of cyst triage.
It set the frame that every later landscape paper filled in: pancreatic cancer is a disease of a few pathways broken by many different genes, so drugs must aim at pathways or their dependencies rather than one rare mutation.
Shares Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia, Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer, Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection, Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers.
Shares Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia, Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.
Shares Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection, Multi-cancer early detection (MCED), Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
Shares Pancreatic acinar cell carcinoma, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
Shares Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA), Pancreatic ductal adenocarcinoma.
Shares Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia, Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development, Pancreatic ductal adenocarcinoma.
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Multi-cancer early detection (MCED), Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.